Ax-4 crew docks with International Space Station after 28-hour rendezvous
An international crew of four in SpaceX's newest Crew Dragon capsule caught up with the International Space Station Thursday and moved in for a problem-free docking to wrap up an automated 28-hour rendezvous that began with blastoff Wednesday.
The capture mechanism in the nose of the Crew Dragon Grace, the fifth and final such spacecraft in SpaceX's fleet, engaged its counterpart in the space-facing port of the forward Harmony module at 6:31 a.m. EDT as the two spacecraft sailed 260 miles above the mid Atlantic Ocean.
The Crew Dragon Grace closes in for docking at the International Space Station after a 28-hour rendezvous.
NASA webcast
With the initial "soft capture" confirmed, the capsule was pulled in and firmly locked in place, power and data umbilicals automatically connected and flight controllers began a series of leak checks to verify an airtight structural seal.
Hatches were finally opened at 8:14 a.m., and Crew Dragon commander Peggy Whitson and her crewmates — Shubhanshu Shukla of India; Sławosz Uznański-Wiśniewski, a European Space Agency astronaut from Poland; and Hungarian engineer Tibor Kapu — floated into the station to hugs and handshakes from the lab's seven long-duration crew members.
Ax-4 crew member and European Space Agency astronaut Sławosz Uznański-Wiśniewski, known by the nickname "Suave" (center), greets space station astronaut Anne McClain (white shirt, back to camera) after floating into the space station.
NASA webcast
Whitson, a retired NASA astronaut, is the most experienced American space flier, logging 675 days in orbit during four previous missions.
On her fifth flight, she is leading the fourth privately-financed commercial space station visit chartered by Houston-based Axiom Space. The company charges up to $70 million or so per seat to carry non-NASA astronauts, professional researchers and others to the space station. Whitson also commanded the company's second space station flight.
Throughout their two-week Ax-4 mission, Whitson and her crewmates plan to carry out a full slate of science research and technology demonstrations, along with interactive educational events in the crew's home countries. They were trained for space station operations and will have full use of the U.S. segment of the orbital lab.
"Peggy, welcome back," station commander Takuya Onishi said when the combined 11-member crew gathered for an official welcoming ceremony. "It's a great honor and privilege to have such a legendary astronaut like you on board with us.
"And Tibor, Shux and Suave, congratulations on your first space flight. We've been waiting for you guys so long, and we are so happy to see your smiling faces. With your arrival, there are 11 astronauts from six countries and all of us are here in order to advance human space exploration and scientific research."
The combined 11-member crew gathered for a welcome aboard ceremony where Whitson, at left with a microphone, pinned astronaut wings on the flight suits of her rookie crewmates (dark shirts, left to right: Hungarian engineer Tibor Kapu, Shubhanshu Shukla of India and Polish astronaut Sławosz Uznański-Wiśniewski.
NASA webcast
Whitson thanked Onishi, saying "you guys are exceptional hosts and hopefully, you'll think we're exceptional guests at the end of a couple of weeks! We're looking forward to getting a lot of work done with you guys."
All told, researchers from 31 countries will be helping evaluate data from the Ax-4 experiments and technology demonstrations. Whitson said before launch the mission "opens up access to countries that might not normally get access to space. So this is very exciting."
Before they reached the space station, the Ax-4 crew beamed down televised comments describing the flight and their expectations.
"Welcome, earthlings, from Grace," Whitson radioed. She revealed the name of the new Crew Dragon moments after reaching orbit Wednesday.
"We are in the newest Dragon capsule, and we are very happy with her," Whitson said. "She's got a little bit of a new-spacecraft smell, and we're loving her a bunch. It's so much fun to be up in space again, always fun to be in space, but it's really fun to be in space with three new astronauts."
During an overnight video call from orbit, Indian test pilot Shubhanshu Shukla shows off the Ax-4 crew's zero-gravity indicator, a small toy named Joy, as the astronauts described their impressions of spaceflight.
Axiom Space
Uznański-Wiśniewski said "it's an amazing feeling to be in orbit for the first time. When I unbuckled for the first time, I didn't feel 100 percent, but then everything settled and when I looked out the window, the view was just stunning."
Shukla, a test pilot in the Indian air force, said of the launch atop a Falcon 9 rocket, "wow, what a night it was."
"When the flight started, it was something, you get pushed back in the seat, it was an amazing flight. And then suddenly, nothing, everything silenced, and you were just floating ... it was an amazing feeling."
Tibor added the crew's thanks "to everyone around the world and every person on the team that made this beautiful day happen."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
17 minutes ago
- Yahoo
Is Danaher's M&A Premium Already Priced In?
Danaher Corporation (NYSE: DHR) is a global science and technology innovator focused on designing, manufacturing, and marketing professional, medical, industrial, and commercial products and services. Following the 2023 spin-off of its Environmental & Applied Solutions segment (now Veralto), Danaher has transformed into a pure-play life sciences and diagnostics company, operating through three primary segments: Biotechnology, Life Sciences, and Diagnostics. Warning! GuruFocus has detected 4 Warning Signs with DHR. Biotechnology (~30% of FY2024 revenue) includes Danaher's bioprocessing and genomic reagents businesses, led by brands like Cytiva and Pall, serving pharmaceutical and biotech companies in biologics production and Sciences (~25% of revenue) offers analytical instruments, microscopy, and lab automation tools used by academic institutions, research labs, and clinical diagnostics developers. Key platforms include Leica Microsystems, SCIEX, and Beckman Coulter Life (~45% of revenue) comprises molecular diagnostics, core laboratory diagnostics, and point-of-care testing systems. Notably, Cepheidone of Danaher's flagship brandsoffers rapid molecular diagnostic testing platforms, particularly for infectious diseases like COVID-19, influenza, and tuberculosis. Danaher reported a better-than-feared quarter, beating both top and bottom line estimates significantly and maintaining its annual guidance. In Q1 FY2025, the company's total sales declined by 1% YoY to $5,741 million from $5,796 million in the previous year's quarter. The decline was due to -1.5% impact from foreign exchange translation, which was partially offset by 0.5% growth through acquisitions and flat core revenue growth. The revenue from the Biotechnology segment grew by 6% YoY to $1,612 million, driven by an increase in core sales from high-growth markets due to a rise in demand. The Life Sciences segment saw a decline of 3.5% YoY to $1,680 million due to a decrease in core sales in the genomics consumables business. Revenue from the Diagnostics segment declined by 3% YoY to $2,449 million due to a decline in the sales of the molecular diagnostic business and lower sales in the China region. The adjusted operating profit declined by 50 bps YoY to 29.6% in the quarter due to product mix, administrative cost structure, currency exchange rates, and acquisition Corporation's Growth & Cash Flow Danaher is positioned as a leading provider of life sciences, diagnostic, and biotechnology equipment after spinning off its environmental business (Veralto) in late 2023. Management's guidance for FY2025 assumes relatively stable end-market demand for the rest of the year (similar to Q1 levels). Against this backdrop, I believe Danaher should grow modestly in 2025, reflecting both macro headwinds (tariffs, academic budget cuts) and continued strength in critical segments. I have mentioned the guidance provided by the management below, and my thesis that should help the company achieve it. For fiscal 2025, Danaher reaffirmed core revenue growth of roughly +3% year-over-year. This is consistent with management's view that market demand (globally) will be relatively consistent with Q1, despite tariffs and other pressures. Adjusted diluted EPS guidance was set at $7.60$7.75 (vs. $7.68 consensus). Notably, management raised its Bioprocessing (biotech) growth forecast to the high-single-digits for 2025 (from a prior 67% outlook). Bioprocessing is Danaher's fastest-growing segment. Robust demand for biologic drug development kits and reagents drove higher Q1 results and should continue to drive growth for the remainder of FY2025. Furthermore, the segment is emerging from the destocking cycle, which should help drive sales. In contrast, the Life Sciences segment forecast was trimmed to essentially flat growth, as funding uncertainties slowed academic and government sales (particularly in the U.S.), and China's medical equipment sector has experienced some softness. This should offset the healthy growth in the Bioprocessing segment. However, any rebound in global R&D spending (or continued Chinese stimulus) could surprise on the upside. The Diagnostics segment (especially Cepheid's molecular tests) is expected to see modest growth: Cepheid's respiratory test sales are forecast to reach around $1.7 billion for 2025, but production volume will return to a normal seasonal level after Q1. Overall, Danaher's portfolio remains tilted toward high-growth medical and diagnostics markets, which underpins its steady outlook despite industry headwinds. A key uncertainty is trade policy: Danaher estimates that current U.S. and European tariffs could add roughly $350 million in costs in 2025. However, the company has long worked to offset these costs via its Danaher Business System (DBS), regionalized manufacturing, and pricing strategies. The company should absorb much of the tariff impact through cost actions and supply-chain adjustments (e.g., surcharges or shifting production) rather than curtailing R&D or major initiatives. Because Danaher's products (lab instruments, diagnostics, and biotech consumables) are often mission-critical in healthcare, I believe its end markets will remain resilient even under tariff pressure. In short, tariffs represent a moderate headwind, but Danaher should largely neutralize the impact by expense reductions and operational flexibility. Margins in the upcoming quarters are expected to contract largely due to seasonality in Cepheid's respiratory testing business. Cepheid is one of Danaher's higher?margin units, and Q2 respiratory kit revenue is assumed to be only about $250 million (vs. ~$625 million in Q1). This sharp seasonal drop in high-margin sales, plus normal diagnostic restructuring costs (e.g., the management of China's reimbursement changes), drives the lower quarter?on?quarter profit margin. In sum, I believe the company's margins should continue to decline and improve in the back half of 2025. As a company built on decades of disciplined capital deployment, Danaher's ability to acquire and successfully integrate businesses has been one of its defining competitive advantages. Flagship acquisitions like Cepheid and Pall have meaningfully strengthened Danaher's diagnostics and bioprocessing platforms, but they also introduce inherent integration risks. These include short-term pressures on margins, incremental R&D and SG&A costs, and the complexities of aligning acquired operations with Danaher's operating structure. While such challenges are typical of any acquisitive strategy, Danaher's track record sets it apart. Over the past 30 years, the company has repeatedly demonstrated its ability to extract synergies, improve productivity, and scale acquisitions effectively, largely driven by the Danaher Business System (DBS). This system institutionalizes continuous improvement, cost efficiency, and cultural integration across its portfolio. Though former CEO Larry Culp played a pivotal role in establishing this M&A discipline, the company's current leadership remains strongly committed to DBS principles, which continue to guide its post-acquisition integration efforts. Moreover, Danaher doesn't pursue acquisitions purely for scale; it focuses on high-quality, strategic assets that complement existing platforms and offer long-term value creation. While integration may temporarily weigh on profitability, especially in the form of restructuring expenses, near-term dilution, or elevated investments in innovation, these are often calculated trade-offs for future operating leverage and market expansion. In essence, what might be viewed as a risk is also one of Danaher's greatest strengths; its consistent ability to turn acquired assets into high-margin, growth-focused businesses that reinforce its leadership in life sciences and diagnostics. As of March 31, 2025, investor activity around Danaher reflected a balanced mix of strategic repositioning and continued confidence in the company's long-term potential. Notably, renowned value investors like Joel Greenblatt (Trades, Portfolio) (+29.03%), Wallace Weitz (Trades, Portfolio) (+23.17%), and Arnold Van Den Berg (Trades, Portfolio) (+14.62%) significantly increased their holdings, signaling optimism about Danaher's focused life sciences and diagnostics trajectory. Ken Fisher (Trades, Portfolio) also added modestly to his position (+1.23%), reinforcing steady institutional support. While some investors like Jefferies Group (Trades, Portfolio), Mario Gabelli (Trades, Portfolio), and George Soros (Trades, Portfolio) trimmed their stakes. Danaher is currently trading at a forward P/E of 25.5x and 22.9x on FY2025 and FY2026 estimated EPS of $7.70 and $8.57, respectively, which is below its five-year average forward P/E of 29.9x. On an EV/EBITDA basis, Danaher trades at approximately 18xhigher than peers such as Thermo Fisher Scientific (P/E ~15x, EV/EBITDA ~13x) and Agilent Technologies (P/E ~21x, EV/EBITDA ~15x). While Danaher's valuation premium may appear elevated relative to peers, it reflects the company's consistent execution, higher exposure to recurring revenue from consumables, and strong margin profile. The market seems cautiously optimistic, pricing in steady growth expectations. For FY2025, Danaher's outlook implies stable and controlled expansion, led primarily by strong bioprocessing demand. Although adjusted operating margins are expected to decline in Q2 due to seasonal normalization in the high-margin Cepheid business, a recovery is anticipated in the latter half of the year. Danaher's long-standing execution discipline, anchored by the Danaher Business System (DBS), equips it to offset macro pressures through operational efficiency and agile supply chain management. With a focused portfolio in mission-critical life sciences and diagnostics, Danaher remains well-positioned to deliver modest yet resilient growth in 2025, supported by strategic capital deployment and a strong competitive moat. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Fox News
an hour ago
- Fox News
Horrified tourists watch as bison boils to death in Yellowstone hot spring
Tourists at Yellowstone National Park witnessed a bison's tragic death on June 21, when the animal fell into the near-boiling waters of the Grand Prismatic Spring at Midway Geyser Basin, near Old Faithful. A witness who posted photos of the incident on social media said the bison took a few steps into a shallow area before turning around and stepping out quickly. The animal then apparently paused before turning back and stepping into a deeper area, where it became trapped and was unable to free itself. "Unfortunately, I witnessed the bison drowning in the Grand Prismatic Springs early yesterday morning. It took a few steps into a shallow area to the right of the pool, it turned around and stepped out very quickly. It stood for a moment, then turned back towards the spring and stepped into a deeper section then couldn't get out despite trying its best. I have a video of it coming up to take its last breath but it's a tough watch," Louise Howard wrote in a Facebook post with the photos. Howard told CBS News that "as hard as it tried, it couldn't get out." Michael Poland, the scientist-in-charge at the Yellowstone Volcano Observatory, told CBS News that while it is rare, it is not unheard of for animals to fall into hot springs. He said scientists have found skeletons at hot springs in the park. According to Poland, the bison died "very quickly" and most likely boiled to death. "This bison carcass is basically sitting in a pool of nearly boiling water, and ... that boiling water will eat away at the organic material, the tissues, and eventually there will just be some bone," Poland said, according to NBC News. The Grand Prismatic Spring is 300 feet wide, and its waters can reach up to 192 degrees Fahrenheit.
CNET
2 hours ago
- CNET
I Used AI to Track My Blood Sugar With My Oura Ring. These 3 Takeaways Surprised Me
I've used my Oura Ring the past few years to track my sleep, recovery and stress. But recently, Oura unlocked a new insight I didn't know I needed: blood sugar levels. I'm constantly experimenting with the latest health tech, so I was naturally intrigued when I learned that Oura Ring partnered with Dexcom's Stelo, a continuous glucose monitor designed for people without diabetes. The goal of this collaboration is to help everyday people like me understand how food and general eating habits impact blood sugar and overall health. "By combining Stelo data with Oura's existing insights, we're empowering members to better understand the cause-and-effect relationships between eating patterns, energy, mood and recovery -- and ultimately make sustainable, science-backed lifestyle changes," Maz Brumand, vice president of product for Oura, told CNET. I tested the Stelo CGM with my Oura Ring for two weeks, and it changed the way I eat and move. This type of biofeedback is helpful for everyone, even those without diabetes. What is continuous glucose monitoring, and why is it important? Your blood sugar, or blood glucose, refers to the measurement of sugar in your blood. According to the Cleveland Clinic, glucose is the main source of energy for your body -- it's what powers your muscles, brain and even your cells. When you eat certain foods (particularly carbohydrates), your glucose rises, and your body responds by releasing insulin to shuttle that sugar into cells for energy or storage. On the flip side, if you experience frequent spikes or crashes (even if you don't have diabetes ), it can impact your energy, sleep, mood and even long-term metabolic health. When your body doesn't need glucose immediately, it stores it as glycogen in your muscles and liver. For people with diabetes, monitoring glucose levels is crucial. But is it important to do the same for the rest of us without a diagnosis? To an extent, I think so. Monitoring your blood sugar throughout the day and seeing how your body reacts to different foods can reveal a lot about your cravings, sleep and metabolic health. "Glucose is a real-time window into metabolic health, which underpins how we feel day to day -- our energy, focus, mood and sleep -- and how resilient we are over time," Brumand says. Oura With the rise of wearable glucose sensors like Stelo, those without diabetes can now get insights into how their eating habits impact their bodies (without finger pricks or a prescription). What is a 'normal' glucose range, and are spikes bad? Before using a CGM, I thought blood sugar was either stable or erratic, with no room for in-between spikes. Once I began tracking my glucose daily, I quickly learned that spikes are completely normal, especially after meals and snacks. Most people will see glucose levels rise and drop throughout the day. According to the American Diabetes Association, a general target range for adults without pre-diabetes or diabetes is between 70 and 140mg/dL (note that Oura also follows this range, and it's what users can expect to see in their graphs). It's also worth highlighting that 70 to 100mg/dL is considered normal for fasting (particularly in the morning before having food), and under 140 mg/dL is common, especially after meals. "Clinical studies show that even in healthy individuals, a moderate glucose spike (rise above 140mg/dL) can occur on a daily basis. In fact, research suggests that healthy adults will live above 140mg/dL for about 30 minutes, up to 2 hours a day, which is usually 1 to 3 short-lived glucose spikes", says Renee Fitton, registered dietitian and director of education at L-Nutra, a nutrition technology company. Oura Fitton further explained that the number and frequency of glucose spikes depend on various factors, primarily what and when you're eating. These spiked can also be affected by other factors like stress level, exercise, dehydration and even whether you have a sunburn. Many glucose monitors use a custom range that adapts to your body's baseline and patterns over time. When looking at your graph, it's important to keep in mind that context and trends matter more than one-off spikes. For example, seeing a spike after dessert isn't a sign that something is wrong. It's a sign that your body is doing its job. What matters most is how quickly your glucose returns to baseline and how often your levels stay elevated over time. "I would not see signs for concern for occasional (one to three times per day) moderate spikes (less than 160mg/dL) that resolve within about 30 mins. When reaching more frequent, especially if they are higher spikes (for example, above 180mg/dL), that take a long time to resolve (over 60 minutes), then there may be concerns about metabolic health," Fitton explained. "A completely flat glucose curve is not something that we aim for; you want some gentle ups and downs as a sign of healthy metabolic flexibility." How I set up the Stelo monitor with my Oura Ring You can order the Stelo sensor directly from Oura ($99 for two sensors). I received a small box with the sensors and easy instructions. Applying it to the back of my upper arm took less than 2 minutes and was surprisingly painless. And yes, there is a small needle involved. I'm terrified of needles, so I spent some time mentally preparing to prick myself, but to my disbelief, I didn't feel it at all. The sound the ejector makes is pretty loud, though. I sometimes think the sound acted as a diversion to my brain, and that's why I didn't feel anything. But, nonetheless, it was a pretty pain-free experience. Once in place, I paired it to the Stelo app, and it automatically reflected within the Oura app. Each sensor tracks your glucose level 24/7 for up to 15 days. Left Image: CGM in the self-injector. Right image: CGM on the back of my right arm. Nasha Addarich Martínez/CNET From the Oura app, I could see how my glucose levels fluctuated throughout the day. You can easily access it at the top of the app, where you also see other data metrics like sleep, heart rate, activity and readiness score (a personalized score, ranging from 0 to 100, that provides a snapshot of how well your body has recovered from the previous day's activities and sleep). How even my 'healthy' food choices raised my blood sugar (and that's OK) One of the most eye-opening parts of my testing was seeing how some of my favorite healthy staples played out on the glucose graph. A great example of this was my favorite pressed juice. I had a pressed juice in the morning that contained pineapple, beets, carrots, ginger, cucumber and lemon. It's nutrient-dense, but it also spiked my glucose above what's considered my healthy range for about 6 minutes (a small window and still considered optimal for my age and overall metabolic health). This was enough to make me rethink how and when I consume fruit-heavy beverages. The next day, I experimented with having a fruit smoothie instead of juice. I made a homemade smoothie with berries, banana, plant-based protein powder, peanut butter, soy milk and oats. This smoothie kept my glucose completely in range (zero minutes above my personal threshold). The added protein and fiber from the fruit, oatmeal, peanut butter and protein powder helped slow the absorption of natural sugars into my bloodstream. Nasha Addarich Martínez/CNET What I learned: Even natural fruit juices can cause glucose spikes, especially when consumed on an empty stomach and without any protein or fiber. Smoothies that include protein, fat and fiber can help keep spikes at bay and help stabilize your energy levels. Balance your meals with protein, fats and fiber Nasha Addarich Martínez/CNET Later that week, I had sushi rolls with a side of edamame for dinner. To my surprise, my glucose levels stayed within range the whole time. Oura Advisor (Oura's AI coach) even pointed out that this food combination offered protein and fiber, which likely contributed to the steady glucose levels. This moment was really encouraging for me. It made me realize that I don't need to drastically change what I eat. By just being more intentional about how I pair my foods, I can drastically improve the impact they have on my blood glucose. Pairing your foods with healthy fats like avocados, nuts, seeds and olive oil can also slow digestion and therefore the absorption of sugars. Fitton explains that this is primarily due to what happens in our digestive tract, even before the nutrients get to our bloodstream. Protein, fiber and healthy fats work in their own way to slow the absorption of simple carbohydrates into the bloodstream, making a slower, more gradual release of sugars into the blood. These factors turn what could be a glucose spike into a steady rise that your body can clear gradually. "The biggest area of concern when managing our blood sugar levels is limiting refined carbohydrates. When you do choose a refined-carb item (a plain cracker, white flour tortilla, cookies, etc.), try to pair it instead of eating it solo: add cheese, nut butter or a handful of edamame to blunt the glucose rise, and choose a higher-fiber version of your carbohydrate source when possible (for example, whole-grain crackers) so the carbs come packaged with their own speed limit," Fitton says. Cake and a walk equal steady blood sugar? One of the more surprising things I learned was that blood sugar stability isn't just about what you eat. It's also about what you do after you eat. One afternoon, I had a slice of cake for a snack. No fiber or protein added, just the cake (I had lunch a few hours before). Instead of my blood sugar spiking, my glucose levels remained steadily in range. The caveat? I took a brisk walk after having my dessert. It wasn't anything strenuous, just a short 15-minute walk around my neighborhood. But it was enough to help my body process and use the glucose more efficiently. "The body knows that exercise demands more energy, and so it helps open up our cells to soak up sugar (energy) and remove it from our blood. A 10-minute walk burns about 30 to 40 calories, and your body will get that energy from circulating glucose or stored glycogen," Fitton explained. After eating cake and going for a walk, my blood sugar saw a slight spike, but stayed within range. Nasha Addarich Martínez/CNET Taking a walk after meals has long been recommended by experts for metabolic health, but seeing the effect in real time made it click for me. I do think that having the cake after having a balanced meal with protein and fiber also contributed to my steady levels of blood sugar. Sometimes, it's not about completely eliminating our favorite treats or carbs, but more so about timing, food pairing and movement. 3 ways I learned to flatten my glucose curve without sacrificing my favorite meals Before using the glucose sensor with Oura, I assumed blood sugar spikes were mostly about foods and how they impact your body. I also thought the only way to manage them was to cut carbs or drastically change my diet. But over these two weeks, I experienced firsthand how and when I eat (and move) matter just as much as what I eat. I learned that these three strategies helped keep my glucose levels in check. Pair carbs and sweets with protein, fiber and healthy fats When I had a berry smoothie with protein powder and soy milk, my glucose levels stayed steady. In contrast, when I had a fruit smoothie earlier that week, my blood sugar levels spiked and crashed more quickly. Takeaway: Carbs on their own, especially refined and processed carbs, can spike blood sugar quickly, but adding protein or fat slows digestion and leads to a more gentle spike. Food pairing examples: Apples and peanut butter, toast with avocado, rice with beans or another it out (especially after sweets) When I had cake as a snack, I was sure my graph would spike dramatically, but it didn't because of my walk (and eating a balanced meal before). A simple walk, even just 10 to 15 minutes, can help offset blood sugar spikes. This small but simple habit helps me now enjoy treats without the crash later. Timing your food matters I also noticed that when I ate higher-carb foods earlier in the day, my body processed them better than when I had them later at night. Breakfast smoothies and bowls kept my levels stable, while the same smoothie after 9 p.m. caused more spikes. "When it comes to blood sugar management, we see that in the morning our body usually has a spike in cortisol (a stress hormone) that can actually help our body take up sugar very quickly and quickly manage blood sugar. Eating in the morning will also calm the cortisol response, reducing the stress on your body. If you wait too long to eat, excess cortisol can create inflammation and also produce larger glucose spikes when you do eat," explained Fitton. Fitton further explained that, conversely, in the evening, the sugar management systems in our bodies start powering down and are not as good at helping blood sugar get into the cells. So it is important to try not to eat too late; otherwise, you'll probably see blood sugar go up and stay up for longer. That doesn't mean you can't eat carbs or treats at night, but eating them earlier in the day when insulin sensitivity tends to be higher can make a real difference.
